Viracta Therapeutics Gets FDA Orphan Drug Designation for Nana-val
November 29 2021 - 8:50AM
Dow Jones News
By Michael Dabaie
Viracta Therapeutics Inc. said the U.S. Food and Drug
Administration granted its product candidate nanatinostat and
valganciclovir, or Nana-val, orphan drug designation for the
treatment of Epstein Barr virus-positive diffuse large B-cell
lymphoma.
DLBCL is the most common subtype of non-Hodgkin lymphoma in the
U.S. and worldwide, the company said.
Viracta shares rose 9.5% to $5.30 in premarket trading.
This is the fourth U.S. FDA orphan drug designation granted for
Nana-val. Viracta has previously received FDA orphan drug
designation for the treatment of T-cell lymphoma, post-transplant
lymphoproliferative disorder and plasmablastic lymphoma.
The FDA grants orphan drug designations to investigational drugs
and biologics that are intended for the treatment of rare diseases
that affect fewer than 200,000 people in the U.S.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
November 29, 2021 08:35 ET (13:35 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Viracta Therapeutics (NASDAQ:VIRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Viracta Therapeutics (NASDAQ:VIRX)
Historical Stock Chart
From Sep 2023 to Sep 2024